Marta Bonotto

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8979817/publications.pdf

Version: 2024-02-01

56 papers	1,159 citations	471509 17 h-index	395702 33 g-index
56 all docs	56 docs citations	56 times ranked	2250 citing authors

#	Article	IF	Citations
1	Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario. Oncologist, 2014, 19, 608-615.	3.7	205
2	Pattern of metastasis and outcome in patients with breast cancer. Clinical and Experimental Metastasis, 2015, 32, 125-133.	3.3	144
3	Immunotherapy for colorectal cancer: where are we heading?. Expert Opinion on Biological Therapy, 2017, 17, 709-721.	3.1	85
4	The <scp>IMPACT</scp> study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 368-377.	7.3	61
5	Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: AÂpropensity score analysis. Breast, 2017, 31, 114-120.	2.2	49
6	Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use. Drugs, 2013, 73, 2003-2015.	10.9	48
7	Treatment of Metastatic Breast Cancer in a Realâ€World Scenario: Is Progressionâ€Free Survival With First Line Predictive of Benefit From Second and Later Lines?. Oncologist, 2015, 20, 719-724.	3.7	46
8	Molecular classifications of gastric cancers: Novel insights and possible future applications. World Journal of Gastrointestinal Oncology, 2017, 9, 194.	2.0	46
9	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. British Journal of Cancer, 2016, 115, 1471-1478.	6.4	45
10	Androgen receptor in estrogen receptor positive breast cancer: Beyond expression. Cancer Treatment Reviews, 2017, 61, 15-22.	7.7	43
11	Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. Cancers, 2019, 11, 1243.	3.7	40
12	Immunotherapy for gastric cancers: emerging role and future perspectives. Expert Review of Clinical Pharmacology, 2017, 10, 609-619.	3.1	33
13	The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. Expert Opinion on Investigational Drugs, 2014, 23, 925-942.	4.1	32
14	Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. Expert Opinion on Biological Therapy, 2017, 17, 365-374.	3.1	27
15	Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. Breast, 2018, 38, 86-91.	2.2	27
16	Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight. Critical Reviews in Oncology/Hematology, 2015, 95, 165-178.	4.4	26
17	Making Capecitabine Targeted Therapy for Breast Cancer: Which is the Role of Thymidine Phosphorylase?. Clinical Breast Cancer, 2013, 13, 167-172.	2.4	22
18	Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. Scientific Reports, 2020, 10, 7010.	3.3	18

#	Article	IF	Citations
19	Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Pagetâ€™s disease of the vulva. International Journal of Gynecological Cancer, 2020, 30, 1672-1677.	2.5	17
20	Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. Oncotarget, 2015, 6, 28716-28730.	1.8	14
21	The distinctive molecular, pathological and clinical characteristics ofBRAF-mutant colorectal tumors. Expert Review of Molecular Diagnostics, 2015, 15, 979-987.	3.1	14
22	First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. Breast, 2021, 57, 104-112.	2.2	14
23	Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer. Frontiers in Oncology, 2020, 10, 550185.	2.8	13
24	Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors. Future Oncology, 2017, 13, 135-144.	2.4	9
25	Pattern of metastatic spread and prognosis of breast cancer biologic subtypes.. Journal of Clinical Oncology, 2014, 32, e12532-e12532.	1.6	9
26	Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. World Journal of Gastroenterology, 2013, 19, 8474.	3.3	9
27	Determinants of Last-line Treatment in Metastatic Breast Cancer. Clinical Breast Cancer, 2018, 18, 205-213.	2.4	8
28	Looking for predictive markers in breast cancer. Lancet Oncology, The, 2015, 16, e1.	10.7	7
29	Beyond RAS: The Role of Epidermal Growth Factor Receptor (EGFR) and its Network in the Prediction of Clinical Outcome During Anti-EGFR Treatment in Colorectal Cancer Patients. Current Drug Targets, 2014, 15, 1225-1230.	2.1	7
30	The SENECA study: Prognostic role of serum biomarkers in older patients with metastatic colorectal cancer. Journal of Geriatric Oncology, 2020, 11, 1268-1273.	1.0	6
31	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. Cancers, 2021, 13, 3504.	3.7	5
32	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. Oncologist, 2022, 27, e561-e570.	3.7	5
33	Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. Expert Opinion on Investigational Drugs, 2015, 24, 1185-1198.	4.1	4
34	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. Breast, 2018, 40, 45-52.	2.2	4
35	Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy. Clinical Colorectal Cancer, 2016, 15, 7-15.	2.3	3
36	Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis. Oncotarget, 2017, 8, 112816-112824.	1.8	3

#	Article	IF	Citations
37	Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. Future Oncology, 2020, 16, 2059-2073.	2.4	2
38	Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.. Journal of Clinical Oncology, 2018, 36, e13079-e13079.	1.6	2
39	Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study.. Journal of Clinical Oncology, 2019, 37, e12507-e12507.	1.6	2
40	Apatinib for gastric cancer: are we moving the antiangiogenic strategy any forward?. Translational Cancer Research, 2016, 5, S765-S771.	1.0	2
41	Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. Future Oncology, 2020, 16, 2645-2660.	2.4	1
42	Association of clinical factors and biological subtypes with different Ca15-3 levels in metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, e24014-e24014.	1.6	1
43	Multidisciplinary Team Meeting Proposal and Final Therapeutic Choice in Early Breast Cancer: Is There an Agreement?. Frontiers in Oncology, 0, 12, .	2.8	1
44	Endocrine therapy in patients with metastatic breast cancers (MBC): Prognosis and measures of outcome.. Journal of Clinical Oncology, 2012, 30, e13070-e13070.	1.6	0
45	Tailored endpoints: A proposal for design of future clinical trials in metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2012, 30, e13058-e13058.	1.6	0
46	Association of body mass index and outcome in advanced breast cancer.. Journal of Clinical Oncology, 2012, 30, 1044-1044.	1.6	0
47	Differences in hormonal receptor status and Ki67 expression between primary breast cancer and metastasis: Is variation related to previous therapy?. Journal of Clinical Oncology, 2014, 32, e22006-e22006.	1.6	0
48	Advanced luminal breast cancer: Who receives chemotherapy as first-line systemic treatment?. Journal of Clinical Oncology, 2014, 32, e11524-e11524.	1.6	0
49	Endocrine maintenance therapy in luminal breast cancer.. Journal of Clinical Oncology, 2015, 33, e11578-e11578.	1.6	0
50	Treatment during the last month of life in advanced cancer patients.. Journal of Clinical Oncology, 2015, 33, e17649-e17649.	1.6	0
51	Endocrine therapy and chemotherapy in luminal metastatic breast cancer.. Journal of Clinical Oncology, 2015, 33, e11573-e11573.	1.6	0
52	Setting and timing of end-of-life care in cancer patients.. Journal of Clinical Oncology, 2017, 35, e21502-e21502.	1.6	0
53	Determinants of adjuvant chemotherapy use in small luminal-like breast cancer.. Journal of Clinical Oncology, 2017, 35, e12010-e12010.	1.6	0
54	Preliminary results from CAMEO-PRO study: Complementary and alternative medicine in oncologyâ€"Physicians inform oncological patients.. Journal of Clinical Oncology, 2017, 35, e21632-e21632.	1.6	0

#	Article	IF	Citations
55	Integration of lymphocyte ratios (LRs) and circulating tumor cells (CTCs) characterization: The interplay between immunity and metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2018, 36, 12039-12039.	1.6	0
56	Abstract P5-14-08: Predictors of relative dose intensity and early dose reduction in patients with metastatic breast cancer treated with palbociclib and endocrine therapy. , 2020, , .		0